My Size, INC Form 4 insider transactions

My Size, Inc. CEO Ronen Luzon acquired 3,750 shares of common stock, signaling confidence in the company's future.

My Size, Inc. Director Oron Branitzky was granted 15,000 restricted shares of common stock, vesting on December 31, 2025.

My Size, Inc. CEO Ronen Luzon reported the acquisition of 275,000 restricted common shares, including shares for his spouse, under the company's 2017 Equity Incentive Plan.

My Size, Inc. Chief Financial Officer Oren Elmaliah was granted 30,000 restricted common shares under the company's 2017 Equity Incentive Plan.

My Size, Inc.'s Chief Growth Officer, Borja Cembrero Saralegui, was granted 110,000 restricted shares of common stock with various vesting conditions.

My Size, Inc. Director Guy Zimmerman was granted 15,000 restricted shares of common stock, aligning his interests with shareholders.

My Size, Inc.'s Chief Product and Operating Officer, Billy Pardo, and his spouse, CEO Ronen Luzon, were granted a total of 275,000 restricted shares under the company's 2017 Equity Incentive Plan.

My Size, Inc. Director Roy Golan was granted 15,000 restricted shares of common stock, vesting on December 31, 2025.

My Size, Inc. Director Arik Kaufman was granted 15,000 restricted common shares under the company's 2017 Equity Incentive Plan, vesting December 31, 2025.

My Size Inc. CEO Ronen Luzon acquired 2,600 shares of the company's common stock at a weighted average price of $0.905, signaling increased insider confidence.

My Size Inc. CEO Ronen Luzon increased his direct beneficial ownership of common stock through open market purchases on November 24 and 25, 2025, signaling confidence in the company.

My Size, Inc. CEO Ronen Luzon filed a Form 4 detailing planned future acquisitions of 13,500 shares of common stock in November 2025 under a Rule 10b5-1 trading plan.

My Size, Inc. has repriced stock options for its CEO, Ronen Luzon, and his spouse, the Chief Product Officer and COO, reducing the exercise price from $8.72 to $1.28 per share following a substantial drop in the company's stock value.

My Size, Inc. announced that its Board of Directors approved the repricing of Director Oron Branitzky's stock options, significantly reducing the exercise price to align with the current closing stock price, following two recent reverse stock splits.

My Size, Inc. (MYSZ) has repriced Chief Financial Officer Oren Elmaliah's stock options, significantly reducing the exercise price from $8.72 to $1.28 per share, reflecting the company's recent stock performance.

My Size, Inc. has repriced stock options for its CPO & COO, Billy Pardo, and CEO Ronen Luzon, reducing the exercise price from $8.72 to $1.28 per share, reflecting the closing stock price on June 4, 2025.

My Size, Inc. has repriced stock options for its Chief Growth Officer, Borja Cembrero Saralegui, to $1.28 per share, aligning with the closing price on June 4, 2025, following a 1-for-8 reverse stock split.

My Size, Inc. has repriced stock options for Director Arik Kaufman to $1.28 per share, aligning with the closing price on June 4, 2025, following two significant reverse stock splits in 2022 and 2024.

Avatar Securities, LLC, a 10% owner of My Size, Inc., decreased its holdings through a series of transactions on December 30, 2024.

My Size, Inc. CEO Ronen Luzon reported the sale of company stock in a recent SEC Form 4 filing.

Billy Pardo, CPO & COO of My Size, Inc., sold 8,000 shares of common stock on December 30, 2024, at prices ranging from $5.10 to $5.40.

Or Kles, CFO of My Size, Inc., sold 2,000 shares of common stock at $5.4 per share on December 30, 2024.